Home Cardiovascular and Metabolic Genetic Markers Brugada Syndrome Genetic Test: SCN5A Gene, Heart Rhythm Risk, and Results

Brugada Syndrome Genetic Test: SCN5A Gene, Heart Rhythm Risk, and Results

By
Vita Library
-
33
Learn how the SCN5A genetic test supports Brugada syndrome diagnosis, what positive, negative, and uncertain results mean, and how findings guide fever precautions, treatment, and family screening.

Brugada syndrome is an inherited electrical heart disorder that can increase the risk of dangerous ventricular rhythms, fainting, cardiac arrest, and sudden death. Its hallmark is a type 1 Brugada pattern on an electrocardiogram (ECG), often most visible in the right precordial leads. The pattern may be present all the time, appear only during fever, or become evident during a carefully supervised sodium-channel blocker test. Genetic testing most often examines SCN5A, the only gene with definitive evidence as a major cause of classic Brugada syndrome. A pathogenic SCN5A variant can support the diagnosis and make family screening more precise, but a negative result does not rule the condition out. Results must be interpreted alongside symptoms, ECG findings, medication exposure, fever history, and the family history of unexplained sudden death. Testing is therefore most useful as part of an inherited arrhythmia evaluation led by clinicians who understand both electrophysiology and cardiovascular genetics.

  • The ECG—not a DNA result alone—establishes the clinical diagnosis of Brugada syndrome.
  • Pathogenic SCN5A variants are found in only a minority of people with a convincing Brugada phenotype.
  • A positive result can enable targeted testing of parents, siblings, children, and other relatives.
  • Fever and certain medicines may unmask the ECG pattern or increase arrhythmia risk.
  • A variant of uncertain significance should not be used by itself to diagnose relatives or justify an implanted defibrillator.

Table of Contents

What an SCN5A test can show

SCN5A provides instructions for making the main sodium-channel protein used by heart muscle cells, often called Nav1.5. Sodium current helps initiate and conduct each heartbeat through the atria, conduction system, and ventricles. Most Brugada-associated SCN5A variants reduce channel function. The resulting loss of sodium current can slow electrical conduction and make the right ventricular outflow region especially vulnerable to the electrical instability associated with a type 1 Brugada pattern and ventricular fibrillation.

A clinical genetic test looks for sequence changes and, when included by the laboratory, deletions or duplications that alter SCN5A function. The strongest result is a variant classified as pathogenic or likely pathogenic and judged compatible with loss of function. That finding can provide a molecular explanation for an established clinical phenotype. It may also clarify related features such as prolonged PR or QRS intervals, progressive conduction disease, sinus-node dysfunction, or atrial arrhythmias in the same family.

SCN5A is unusual because different changes in the same gene can produce different disorders. Loss-of-function variants are associated with Brugada syndrome and conduction disease, while some gain-of-function variants cause long QT syndrome type 3. Other variants can be associated with dilated cardiomyopathy, atrial fibrillation, or overlapping electrical phenotypes. The laboratory classification must therefore be interpreted together with the precise variant mechanism and the person’s ECG rather than simply reading “SCN5A positive.” A result linked to one SCN5A condition cannot automatically be assumed to cause another.

Current evidence supports SCN5A as the principal definitive gene for routine Brugada genetic testing. Some commercial panels include many additional genes historically reported in small studies. Most have limited, disputed, or phenotype-specific evidence and can increase the chance of uncertain findings without improving diagnostic clarity. A focused SCN5A analysis or a carefully curated inherited arrhythmia panel is usually more informative than indiscriminate broad testing. A broader cardiovascular genetic panel may be reasonable when the phenotype overlaps with cardiomyopathy, long QT syndrome, conduction disease, or another inherited rhythm disorder.

A genetic result cannot measure a person’s immediate rhythm, prove that a fainting episode was arrhythmic, or predict the exact age at which an event will occur. It also cannot substitute for an ECG. Many people with clinically diagnosed Brugada syndrome do not have an identifiable pathogenic SCN5A variant, and some carriers of a familial variant never develop a diagnostic ECG or serious symptoms. This variable expression is called reduced or incomplete penetrance.

How Brugada syndrome is diagnosed

The defining finding is a type 1 Brugada ECG pattern: coved ST-segment elevation in the right precordial leads followed by a negative T wave. Leads V1 and V2 may be recorded in their standard positions and in higher intercostal spaces, where the pattern can be easier to detect. The ECG is dynamic. A person can have a normal tracing on one day and a diagnostic tracing during fever, after exposure to a sodium-channel blocking medicine, or at another time.

A spontaneous type 1 pattern carries different diagnostic and prognostic weight from a pattern seen only after drug provocation. When the resting ECG is nondiagnostic but clinical suspicion remains substantial, an electrophysiology team may consider a controlled challenge with a sodium-channel blocker. This is not a home test or a routine screening procedure. It requires continuous ECG monitoring, resuscitation capability, an experienced protocol, and careful selection because false-positive or ambiguous responses can occur.

Clinicians interpret the tracing with the clinical setting. Findings that strengthen concern include documented ventricular fibrillation or polymorphic ventricular tachycardia, resuscitated cardiac arrest without another explanation, arrhythmic syncope, nocturnal agonal breathing, a spontaneous type 1 ECG, or a family history of Brugada syndrome or unexplained sudden death. Symptoms such as palpitations and fainting are important but not specific; vasovagal syncope, seizures, orthostatic intolerance, and structural heart disease can resemble an inherited electrical disorder.

Other causes of a Brugada-like ECG must be considered. Acute ischemia, pulmonary embolism, electrolyte disturbance, mechanical compression, severe metabolic illness, and certain drug toxicities can create “phenocopies.” Echocardiography or cardiac magnetic resonance imaging may be used when structural disease is possible. Routine laboratory testing can identify electrolyte or metabolic abnormalities. The goal is not merely to label the ECG but to understand whether it represents an inherited syndrome, a transient acquired pattern, or another heart condition.

The diagnosis is consequently an integration of electrical evidence, symptoms, family history, and exclusions. A pathogenic SCN5A result supports that integration, particularly when the clinical findings are characteristic, but the DNA finding is not an independent replacement for it. Likewise, a person with a convincing spontaneous type 1 pattern may still have Brugada syndrome when genetic testing is negative.

Who may benefit from testing

Testing is most appropriate for an index patient—the first evaluated person in a family—who has a type 1 Brugada ECG pattern in standard or high right precordial leads. It is especially useful when the pattern is spontaneous, when there has been cardiac arrest or likely arrhythmic syncope, or when the family history suggests inherited sudden death. Testing can also be considered when a type 1 pattern is induced by a sodium-channel blocker and there are supporting symptoms or family findings.

The main goals should be established before the sample is collected. In a clearly affected patient, the test may seek a molecular explanation and create a marker for relatives. In a person with an uncertain ECG, testing may contribute evidence but usually cannot resolve the question by itself. In a family where a pathogenic variant is already known, targeted testing of that exact variant is far more informative than ordering a new broad panel.

Testing may be discussed after unexplained cardiac arrest, particularly when coronary, structural, toxic, and metabolic causes have been evaluated. However, the test ordered in that setting may need to cover several inherited arrhythmia and cardiomyopathy genes because the initial phenotype can be nonspecific. The same applies to families with overlapping conduction disease, atrial arrhythmias, ventricular dysfunction, or sudden death at different ages.

Genetic testing is usually low yield when ordered for an isolated, nondiagnostic type 2 or type 3 Brugada-like pattern without symptoms, a relevant family history, or a confirmed type 1 tracing. Testing healthy people with no familial variant and no clinical indication can generate uncertain results that create anxiety rather than clarity. Consumer genomic data are not a substitute for a clinically validated assay, especially because raw-data interpretation may miscall rare variants or omit important regions.

Pretest genetic counseling helps define what a useful result would look like. The discussion should cover the modest detection rate, reduced penetrance, possible implications for relatives, limitations of uncertain variants, privacy and insurance considerations that vary by country, and the possibility of identifying an overlapping SCN5A phenotype. Adults should also consider how they want results communicated to relatives if a familial variant is found.

How testing is performed

The test usually requires a blood sample or saliva specimen. Blood is often preferred when a high-quality DNA source is needed, but both can be suitable when collected according to laboratory instructions. Fasting is not required. Medicines should not be stopped merely because a genetic sample is being collected, although the clinical team may separately review drugs that affect the ECG.

A focused assay sequences the coding regions and relevant splice boundaries of SCN5A. Many laboratories also assess copy-number changes, although large deletions and duplications are less common than single-letter sequence variants. A curated multigene panel may be selected if the phenotype is not purely Brugada syndrome. Exome or genome sequencing is generally reserved for unresolved, complex, or research-oriented cases and does not guarantee an answer.

The ordering clinician should send the laboratory detailed phenotype information: ECG pattern, whether it was spontaneous or provoked, symptoms, age at onset, conduction measurements, imaging findings, and family history. This information can materially affect variant interpretation. A change that is plausible in a patient with a classic loss-of-function phenotype may be less convincing in someone with a normal ECG and no family history.

Laboratories commonly use five categories: pathogenic, likely pathogenic, variant of uncertain significance, likely benign, and benign. Classification incorporates population frequency, predicted effect, functional studies, segregation with disease, published cases, and the established mechanism of SCN5A-related disease. The report should identify the transcript used, the DNA and protein change, classification, evidence summary, and testing limitations.

Results may take several weeks. Before acting on an unexpected finding, a cardiovascular genetics team may confirm that the laboratory is clinically accredited, review the original sequence evidence, compare the classification with expert databases, and determine whether the variant has been reclassified. Variant interpretation changes as evidence accumulates, so periodic reanalysis can be appropriate, especially for an unresolved uncertain result.

Understanding positive, negative, and uncertain results

A positive result means that the laboratory identified a pathogenic or likely pathogenic variant that fits the known disease mechanism. In a person with a diagnostic ECG, it supports an SCN5A-related Brugada syndrome diagnosis. It also permits targeted testing of relatives. The result does not state that a life-threatening event is inevitable, and it does not assign a precise individual probability. Carriers can range from asymptomatic with normal resting ECGs to people with conduction disease, spontaneous type 1 patterns, syncope, or cardiac arrest.

The exact variant matters. Truncating variants that clearly disrupt the channel, well-established splice variants, and functionally proven loss-of-function missense variants may have stronger evidence than a rare missense change with limited data. Some studies suggest that variant type or location may contribute prognostic information, but these observations are not used in isolation to determine treatment. Clinical history remains central.

A negative result means no reportable disease-causing variant was found with the method used. It does not exclude Brugada syndrome because most clinically affected people do not receive a molecular diagnosis. It may reflect an undiscovered gene, a variant outside the regions tested, a complex genetic contribution, technical limitations, or a condition that is primarily established by the ECG. Management should continue to follow the phenotype. When no familial pathogenic variant has been identified, relatives cannot be cleared by a negative panel alone and may still need clinical screening.

A variant of uncertain significance, or VUS, means the available evidence is insufficient to call the change disease-causing or harmless. A VUS should not establish the diagnosis, trigger an implanted cardioverter-defibrillator, or be used for predictive testing of unaffected relatives. Testing selected affected relatives may sometimes help the laboratory determine whether the variant tracks with disease, but testing should be planned by genetics professionals rather than performed as unsupervised family screening. A practical explanation of this category is available in the guide to pathogenic, benign, and uncertain genetic variants.

Likely benign and benign variants are not considered an explanation for the phenotype. They should not be used to label family members as affected. Reports may also mention carrier status or incidental findings depending on the test and consent, although focused SCN5A testing minimizes unrelated discoveries.

Any result should be reconciled with the pedigree. If a supposedly causative variant is present in many older relatives with normal ECGs, that does not automatically disprove it because penetrance can be incomplete, but it may reduce confidence depending on the family size and variant evidence. Conversely, absence of the variant in a clearly affected relative can suggest that the family has more than one cause, that the clinical diagnosis differs, or that the variant was overinterpreted.

How results affect risk and treatment decisions

Risk assessment is driven primarily by clinical events and ECG features. A person who has survived ventricular fibrillation or an otherwise unexplained cardiac arrest is in a very different category from an asymptomatic carrier identified through family testing. Arrhythmic syncope and a spontaneous type 1 pattern also weigh heavily. The electrophysiologist may consider age, sex, conduction intervals, documented arrhythmias, family context, and other findings, but no single test perfectly predicts future ventricular fibrillation.

An implanted cardioverter-defibrillator (ICD) is the most effective protection against recurrent lethal ventricular arrhythmia in appropriately selected high-risk patients, particularly survivors of cardiac arrest. It also carries meaningful burdens: inappropriate shocks, lead failure, infection, repeated procedures, psychological distress, and device complications over decades. A pathogenic SCN5A variant alone is generally not an indication for an ICD in an asymptomatic person without a diagnostic risk profile.

Some patients with recurrent ventricular fibrillation or electrical storms may be treated with quinidine under specialist supervision. Catheter ablation targeting abnormal electrical substrate in the right ventricular outflow region may be considered in selected people with recurrent events or repeated ICD therapies. These are electrophysiology decisions, not automatic consequences of a genetic report.

Programmed electrical stimulation may be used in selected circumstances, but its predictive value is imperfect and practices vary. Ambulatory monitoring can investigate palpitations, pauses, or intermittent conduction disease. A pacemaker may be relevant when significant bradycardia or conduction block predominates, while an ICD is designed to terminate malignant ventricular rhythms. The choice depends on the person’s complete electrical phenotype.

SCN5A carriers may require attention to overlap features. Progressive PR or QRS prolongation, sinus-node dysfunction, atrial fibrillation, or ventricular dysfunction may justify periodic ECGs, ambulatory monitoring, and imaging. This does not mean every carrier will develop multiple conditions. It means follow-up should be tailored rather than limited to a one-time Brugada label.

Fever, medicines, procedures, and daily life

Fever can reduce sodium-channel function further and may reveal a type 1 ECG pattern or provoke arrhythmia in susceptible people. Individuals with diagnosed Brugada syndrome—and relatives with a known pathogenic SCN5A variant who have been given the same plan—are generally advised to treat fever promptly, maintain hydration, and follow individualized instructions about when to obtain an ECG or seek emergency care. Urgent evaluation is appropriate for fainting, seizure-like activity, nocturnal gasping, sustained palpitations with weakness, or signs of cardiac arrest.

Medication review is essential because some antiarrhythmics, psychiatric medicines, anesthetic agents, and other drugs can worsen the Brugada ECG or arrhythmic risk. Patients should use an up-to-date specialist-maintained medication list and show it to prescribers, pharmacists, emergency clinicians, dentists, and anesthesia teams. A medicine should not be stopped abruptly without advice when withdrawal could also be harmful. The prescribing clinician can select an alternative or arrange monitoring when a potentially relevant drug is necessary.

Recreational cocaine and excessive alcohol intake can increase arrhythmic risk and should be avoided. Severe electrolyte disturbance from vomiting, diarrhea, crash dieting, or dehydration also deserves prompt correction. Ordinary exercise is not universally prohibited, and recommendations should be individualized. Unlike some cardiomyopathies, Brugada syndrome is not primarily an exercise-triggered disease, but extreme heat, dehydration, or symptoms during activity warrant caution and medical review.

Before surgery or sedation, the anesthesia team should know the diagnosis and any SCN5A result. Planning may include drug selection, temperature control, electrolyte monitoring, continuous ECG observation, and postoperative surveillance. Pregnancy is often tolerated, but medication and fever plans should be reviewed in advance. The diagnosis is not itself a reason to avoid pregnancy; reproductive choices can be discussed with cardiology and genetics professionals.

A written emergency plan is useful. It can state the diagnosis, device status, medications to avoid, fever instructions, electrophysiology contact details, and what relatives should tell emergency services. Family members may benefit from cardiopulmonary resuscitation training and access to an automated external defibrillator where advised, especially in a household with someone who has had a prior arrest.

Family screening and testing in children

Brugada syndrome related to SCN5A is usually inherited in an autosomal dominant manner. Each child, sibling, or parent of a person with a heterozygous pathogenic variant has a 50% chance of carrying that variant, although the chance of developing a diagnostic ECG or symptoms is lower and cannot be predicted exactly. The variant may be inherited from a parent with subtle findings, or it may have arisen de novo.

Once a familial pathogenic or likely pathogenic variant is established, relatives can have targeted testing for that exact change. A relative who tests positive should receive an ECG-based evaluation and a personalized fever and medication plan. A relative who tests negative for a well-established familial variant can usually be released from variant-specific surveillance, unless symptoms, an abnormal ECG, or evidence of a second familial condition indicate otherwise.

When the affected index patient has negative genetic testing, first-degree relatives may still need clinical screening because there is no molecular marker to exclude inherited susceptibility. Screening can include a history, resting ECG with right precordial leads placed in standard and higher positions, and further evaluation based on findings. Drug provocation is not automatically performed in every relative; it is reserved for carefully selected cases under an experienced team.

Testing children is appropriate when a familial pathogenic SCN5A variant is known because the result can change fever management, medication precautions, and clinical follow-up during childhood. Pediatric carriers may have conduction abnormalities or fever-induced ECG changes even when they are otherwise well. Parents should receive specific instructions rather than being left with a generic warning about fever. Schools and caregivers may need a concise action plan.

A negative targeted result in a child can relieve the family from unnecessary restrictions related to that variant. A VUS should not be used for predictive testing of a healthy child because it cannot reliably sort risk. If the family’s only finding is uncertain, clinical evaluation remains the appropriate approach while the variant is monitored for reclassification.

Family communication can be emotionally difficult, particularly after a sudden death. A genetic counselor can prepare a letter that explains the result, who is at risk, and how relatives can access testing without disclosing more personal information than necessary. The purpose is not to create alarm. It is to identify the smaller group that needs precautions and follow-up while reassuring relatives who did not inherit a confirmed familial variant.

References

Disclaimer

This article is for general educational purposes and does not provide medical advice, diagnosis, or emergency guidance. Brugada syndrome evaluation and genetic results should be interpreted by a qualified cardiologist, electrophysiologist, and genetics professional using the person’s ECGs, symptoms, medications, and family history. Anyone with fainting, seizure-like activity, sustained palpitations, or signs of cardiac arrest should seek urgent medical care.

RELATED ARTICLESMORE FROM AUTHOR